Heart Disease News and Research

Latest Heart Disease News and Research

American Red Cross encourages public to be trained in full CPR and use of AEDs

"Articles published today in The New England Journal of Medicine (NEJM) cite a pair of studies on Compression-Only Cardiopulmonary Resuscitation (CPR), sometimes called continuous chest compressions, Hands-Only CPR, or cardio cerebral resuscitation (CCR).

29 Jul 2010

Rotigotine provides clinically relevant improvements in RLS symptoms: Study

UCB today announced the results of a 6-month, randomized, double-blind, placebo-controlled clinical study, published in the journal Movement Disorders, showing that Neupro® (rotigotine transdermal system, 2 and 3 mg/24 hours) provided sustained, clinically relevant improvements in symptoms of Restless Legs Syndrome (RLS). The study also showed high rates of complete remission seen with rotigotine 2 mg or 3 mg/24 hours.

29 Jul 2010

Positive results from phase I clinical trial of MultiStem in patients with AMI announced

Angiotech Pharmaceuticals, Inc. and partner Athersys, Inc. announced positive results from its phase I clinical trial of MultiStem, its allogeneic cell therapy product, administered to individuals following acute myocardial infarction, more commonly referred to as a heart attack.

29 Jul 2010

The Children's Hospital constructs new LEED-certified patient tower

The Children's Hospital has begun the construction of a 10-story, 350,000-square-foot addition. The $230 million expansion of a new patient tower initially will have 124 beds, with two floors of shelled space for additional future beds, bringing the total number of patient beds at Children's to around 500 upon full completion. The expansion also is expected to bring approximately 500 new jobs to the hospital's workforce. Children's anticipates admitting patients in the LEED-certified tower beginning in late 2012.

29 Jul 2010

Merit Medical second-quarter revenues increase 16% to $74.9 million

Merit Medical Systems, Inc., a leading manufacturer and marketer of proprietary disposable medical devices used in interventional and diagnostic procedures, particularly in cardiology, radiology and gastroenterology, today announced record revenues of $74.9 million for the quarter ended June 30, 2010, an increase of 16% over revenues of $64.8 million for the quarter ended June 30, 2009. Revenues for the six-month period ended June 30, 2010 were a record $142.4 million, compared with $123.2 million for the corresponding period in 2009, a gain of 16%.

29 Jul 2010

Study reveals high rate of atrial fibrillation in patients with early stages of CKD

Millions of Americans in the early stages of chronic kidney disease (CKD) are at an increased risk of having atrial fibrillation (AF) - a major risk factor for stroke - according to new research by investigators at Wake Forest University Baptist Medical Center.

29 Jul 2010

Sanofi-aventis U.S joins Dispensary of Hope's Continued Access Program

The Dispensary of Hope is pleased to announce that sanofi-aventis U.S., the U.S. affiliate of sanofi-aventis, a leading global pharmaceutical company, has become the latest pharmaceutical company to participate in the Dispensary's Continued Access Program, which provides uninsured patients with access to medicines that they otherwise couldn't afford.

29 Jul 2010

FDA Advisory Committee recommends approval of AstraZeneca's ticagrelor for Acute Coronary Syndromes

AstraZeneca today announced that the US Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee recommended the FDA approve AstraZeneca's investigational drug ticagrelor for the reduction of thrombotic events in patients with Acute Coronary Syndromes.

29 Jul 2010

Response Biomedical closes $8 million common share private placement

Response Biomedical Corporation announced today that it has closed its previously announced private placement of common shares for gross proceeds of approximately $8 million. The Company issued 13,333,333 common shares at a price of C$0.60 per share.

29 Jul 2010

Athersys reports positive results from MultiStem phase I clinical trial in heart attack patients

Athersys, Inc. announced today positive results from its phase I clinical trial of MultiStem®, its allogeneic cell therapy product, administered to individuals following acute myocardial infarction (AMI), more commonly referred to as a heart attack. The study results, based on four months of post-treatment patient data, demonstrate that MultiStem was well tolerated at all dose levels and also suggest improvement in heart function in treated patients.

29 Jul 2010

Inhibition of MMPs can offer therapeutic benefit in Huntington's disease: Study

A new study reveals that an enzyme linked with multiple disorders is also involved in the generation of toxic, neuron-killing protein fragments in Huntington's disease (HD). The research, published by Cell Press in the July 29 issue of Neuron, provides insight into Huntington's pathology and proposes new therapeutic strategies for this devastating incurable disease.

29 Jul 2010

VaxGen completes merger transaction with diaDexus

VaxGen, Inc. announced today the completion of its merger transaction with diaDexus, Inc., a diagnostics company focused on the development and commercialization of patent-protected in vitro diagnostic products addressing unmet needs in cardiovascular disease.

29 Jul 2010

AMAG attributes increased second-quarter revenues of $18.8 million to Feraheme

AMAG Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, today reported unaudited consolidated financial results for the second quarter and six months ended June 30, 2010. For the second quarter, AMAG reported total revenue of $18.8 million, including $16.0 million of Feraheme® (ferumoxytol) Injection for intravenous (IV) use net product revenues.

29 Jul 2010

HemoBioTech receives patent for HemoTech treatment of acute blood loss

HemoBioTech announced today the issuance of a new patent US 7,759,306 B2, Methods of Treating Acute Blood Loss. HemoBioTech has an exclusive worldwide license from Texas Tech University to commercialize the technology. The new patent continues to May 16, 2026. The major advance in HemoTech is the presence of Adenosine which has anti-inflammatory activity.

29 Jul 2010

HIV drug can raise the risk of heart disease: Study

There are a handful of drugs effective in treating HIV/AIDS. However new research shows that some of these drugs can increase the risk of heart attacks. The results come from a Garvan Institute of Medical Research study involving 20 people, 10 taking the drug Ritonavir and 10 others the drug Raltegravir for one month.

28 Jul 2010

Aging thalidomide victims to receive $50 million in compensation

Thalidomide was sold in a number of countries across the world from 1957 until 1961 when it was withdrawn from the market after being found to be a cause of birth defects in what has been called "one of the biggest medical tragedies of modern times".

28 Jul 2010

Intercept signs CRADA with NIDDK for study of obeticholic acid in nonalcoholic steatohepatitis

Intercept Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing novel therapeutics for chronic fibrotic and metabolic diseases, today announced the signing of a cooperative research and development agreement (CRADA) with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health to conduct a double blind, multi-center, study to evaluate the effects of obeticholic acid in patients with nonalcoholic steatohepatitis (NASH).

28 Jul 2010

CompuMed signs agreement with Lincoln High School Learning Centers

CompuMed, Inc., a telemedicine and medical informatics company, has entered into an agreement with the San Diego Unified School District's Lincoln High School Learning Centers to provide CompuMed's CardioGramKids electrocardiogram telemedicine technologies and services to the four schools that comprise the Lincoln High Learning Centers: the Lincoln High Schools of Public Safety, Science & Engineering, Arts and Social Justice.

28 Jul 2010